Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash from Operations: 2019-2025

Historic Cash from Operations for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -$8.9 million.

  • Biodesix's Cash from Operations rose 16.79% to -$8.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year increase of 50.48%. This contributed to the annual value of -$48.6 million for FY2024, which is 112.72% down from last year.
  • Latest data reveals that Biodesix reported Cash from Operations of -$8.9 million as of Q3 2025, which was down 35.19% from -$6.6 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Cash from Operations registered a high of $1.1 million during Q2 2021, and its lowest value of -$18.6 million during Q2 2024.
  • Over the past 3 years, Biodesix's median Cash from Operations value was -$8.6 million (recorded in 2025), while the average stood at -$8.7 million.
  • Per our database at Business Quant, Biodesix's Cash from Operations skyrocketed by 125.33% in 2021 and then tumbled by 2,081.96% in 2024.
  • Biodesix's Cash from Operations (Quarterly) stood at -$10.2 million in 2021, then declined by 17.17% to -$11.9 million in 2022, then declined by 2.80% to -$12.3 million in 2023, then surged by 66.65% to -$4.1 million in 2024, then increased by 16.79% to -$8.9 million in 2025.
  • Its last three reported values are -$8.9 million in Q3 2025, -$6.6 million for Q2 2025, and -$8.6 million during Q1 2025.